Integrin β3 links therapy resistance and cancer stem cell properties
- PMID: 24914436
- DOI: 10.1038/ncb2960
Integrin β3 links therapy resistance and cancer stem cell properties
Abstract
Heterogeneity in tumour cell properties underlies many treatment failures. Understanding the sources of such heterogeneity has proved to be challenging, but remains critical to improving patient outcomes. Integrin α(v)β₃ expression in multiple types of solid tumour stem cells is now shown to control a pro-survival pathway that contributes to therapy resistance.
Comment on
-
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20. Nat Cell Biol. 2014. PMID: 24747441 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
